Sort   by:  
 Page size 
UnknownKampinos National Park: a risk area for spotted fever group rickettsioses, central Poland?
Not available
S-EPMC5061876 | biostudies-literature
UnknownEfficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study.
Not available
S-EPMC11782106 | biostudies-literature
UnknownEfficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Not available
S-EPMC3536944 | biostudies-literature
UnknownEfficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.
Not available
S-EPMC11499533 | biostudies-literature
UnknownDetection and quantification of Anaplasma phagocytophilum and Babesia spp. in Ixodes ricinus ticks from urban and rural environment, northern Poland, by real-time polymerase chain reaction.
Not available
S-EPMC4412423 | biostudies-literature
UnknownA randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis.
Not available
S-EPMC12672812 | biostudies-literature
UnknownA phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Not available
S-EPMC4818886 | biostudies-literature
UnknownSwitching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Not available
S-EPMC6001519 | biostudies-literature
UnknownPhase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Not available
S-EPMC5765475 | biostudies-literature
UnknownEfficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
Not available
S-EPMC6251842 | biostudies-literature
Sort   by:  
 Page size